Naked DNA/Biomarker Protein Biodistribution Analysis

Naked DNA or plasmid DNA is frequently used as vector in DNA vaccination and gene therapy applications. Due to the good biocompatibility of plasmid DNA, their cost-efficient production and long shelf life, many researchers aimed to develop DNA vaccine-based immunotherapeutic strategies for treatment of infections and cancer, but also autoimmune diseases and allergies.

Creative Bioarray offers the RNA in situ hybridization (RNA ISH) and Biomarker protein immunohistochemistry (IHC) assay to visualize and monitor the delivery and biodistribution of naked DNA and related proteins to access the specificity and efficacy of these therapies. Our Naked DNA/Biomarker Protein Biodistribution Analysis services can help you validate and accelerate your gene therapy development.

RNA in situ hybridization (RNA ISH) combined with Biomarker protein immunohistochemistry (IHC) assay possesses several advantages in the development process of naked DNA vaccines:

• Specificity: Both RNA ISH and IHC assays have high specificity which enhances the validity of measured outcomes. This boosts the performance and reliability of the developed vaccine by accurately determining the transgene expression and protein production.
• Spatial Resolution: This combination technique offers a significant spatial resolution. It allows to visualize and localize the naked DNA, specific mRNA transcripts and proteins within individual cells. This detailed cellular level evaluation furnishes crucial insights into the cellular responses triggered by the introduced DNA vaccines.
• Quantifiability: RNA ISH assay can quantify the mRNA molecules present in each cell. This, along with the protein quantification by biomarker IHC, helps in the accurate measurement of vaccine-induced cellular responses.
• Versatility: Both techniques are versatile and can be adapted for different target genes and proteins. This allows the evaluation of vaccines designed for different pathogens or diseases.
• Multiplex Detection: RNA ISH with IHC has the potential for simultaneous detection of multiple targets which is vital in understanding complex cellular responses to DNA vaccines.

Hence, the combination of these techniques provides a comprehensive understanding of the vaccine's mechanism, improving the development process by identifying potential drawbacks and inefficiencies at an early stage, ultimately leading to better vaccine design and performance.

Features of Naked DNA/Biomarker Protein Biodistribution Analysis

(1) Detect and identify cellular subtypes
(2) Naked DNA analysis
(3) RNA molecule analysis
(4) Protein analysis
(5) Custom probes designed within 1-2 weeks
(6) Fastest turnaround time

Benefits of Naked DNA/Biomarker Protein Biodistribution Analysis

(1) Detect and identify cellular subtypes
(2) Visualize naked DNA with morphological context
(3) Visualize gene regulation with morphological context
(4) Validate protein biomarkers in intact tissues
(5) Assess naked DNA therapeutic delivery mechanism
(6) Evaluate biodistribution and efficacy of therapy
(7) Add a visual dimension to heterogeneous tissue biology and analysis

Creative Bioarray offers Naked DNA/Biomarker Protein Biodistribution Analysis for you as follows:

• Probe design
• Probe synthesis
• ISH staining
• IHC staining
• Imaging
• Data analysis

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your Naked DNA/Biomarker Protein Biodistribution Analysis partner.

References

1. Prazeres, D.M.F.; Monteiro, G.A. Plasmid Biopharmaceuticals. Microbiol. Spectrum 2014
2. Fioretti, D.; Iurescia, S.; Rinaldi, M. Recent advances in design of immunogenic and effective naked DNA vaccines against cancer. Recent Pat. Anti-Canc. Drug Discov. 2014, 9, 66–82.
3. Scheiblhofer, S.; Thalhamer, J.; Weiss, R. DNA and mRNA vaccination against allergies. Pediat. Allergy Immu. 2018.
4. Zhang, N.; Nandakumar, K.S. Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases. Vaccine 2018, 36, 3208–3220.
5. Maslow, J.N. Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. Hum. Vacc. Immunother. 2017, 13, 2918–2930.
6. Weniger, B.G.; Anglin, I.E.; Tong, T.; Pensiero, M.; Pullen, J.K. Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015. Vaccine 2018, 36, 427–437.
7. Tiptiri-Kourpeti, A.; Spyridopoulou, K.; Pappa, A.; Chlichlia, K. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Pharmacol. Therapeut. 2016, 165, 32–49.
8. Marino, M.; Scuderi, F.; Provenzano, C.; Bartoccioni, E. Skeletal muscle cells: From local inflammatory response to active immunity. Gene Ther. 2011, 18, 109–116.
9. Hengge, U.R.; Chan, E.F.; Foster, R.A.; Walker, P.S.; Vogel, J.C. Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat. Genet. 1995, 10, 161–166.
10. Porgador, A.; Irvine, K.R.; Iwasaki, A.; Barber, B.H.; Restifo, N.P.; Germain, R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 1998, 188, 1075–1082.
11. Bai, H.; Lester, G.M.S.; Petishnok, L.C.; Dean, D.A. Cytoplasmic transport and nuclear import of plasmid DNA. Biosci. Rep. 2017, 37.